That is what an evidence base looks like for a GHRH analogue: hundreds of randomised patients, a year of treatment, a hard endpoint, a regulators review, and an honest negative finding about durability
Modified GRF (1-29) + Ipamorelin Chemical Formula: Composite peptide blend (multiple sequences) CAS Number: Mixture (individual components vary) Molecular Weight: Composite (component-dependent) Peptide Length: Multiple peptides (varied amino acid lengths) Purity: 99.0% (validated by Certificate of Analysis for each component) Appearance: White to off-white lyophilized powder Solubility: Fully soluble in water (HO) Quality Verification: Confirmed by RP-HPLC analysis Storage Conditions: Store dry at 28 C
The two most clinically relevant GHRH peptides are: CJC-1295 (without DAC): Promotes physiologic GH pulses, often paired with a growth hormonereleasing peptide (GHRP) like Ipamorelin for synergistic effects
Growth hormone levels drop roughly 15% per decade after age 30, and the effects show up as slower recovery, stubborn body fat, lower energy, and less muscle
As an outcome of a major chemistry programme, ipamorelin was identified within a series of compounds lacking the central dipeptide Ala-Trp of growth hormone-releasing peptide (GHRP)-1
Its components are studied for blood supply, repair-cell movement, collagen, and inflammation rather than muscle growth. No controlled KLOW trial has measured muscle growth or delayed-onset muscle soreness
